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bNucleic acid immunization describes the inoculation of
DNA (usually a closed circular plasmid, although linear
PCR fragments may be used) or RNA with the intent of
inducing an immune response to the protein(s) (usually
microbial) encoded therein. It is a relatively recent addition
to the vaccine arsenal, and no nucleic acid-based vaccine
has yet been approved for clinical or veterinary use. How-
ever, experimental studies have demonstrated that plas-
mid-based DNA vaccines can induce immune responses in
humans (Wang et al., 1998), and the approach is currently
being evaluated in several clinical trials. There are good
grounds for optimism; the method has many advantages,
not the least of which is its enormous flexibility, and it
confers protective immunity in a multitude of animal models
(reviewed by Donnelly et al., 1997; Hassett and Whitton,
996). Nevertheless, there remains much room for improve-
ent; nucleic acid vaccines in general appear not to induce
s strong responses as do conventional (live attenuated)
accines, and consequently many laboratories are attempt-
ng to enhance the immunogenicity of these promising
accine candidates. Here we describe some of the ave-
ues which have been explored; since the great majority of
tudies have employed plasmid DNA, in this minireview we
ocus on DNA vaccines.
DNA vaccines may be administered in several ways.
erhaps the two most common are, first, intramuscular
njection, in which the plasmid DNA is taken up by muscle
ells and the genes are expressed therein; and, second,
dministration by some form of intradermal inoculation,
ometimes using the “gene-gun,” in which tiny gold parti-
les coated with DNA are impelled into the skin. Following
uch inoculation, the DNA is taken up by and expressed in
pecialized antigen-presenting cells (APCs) called Langer-
ans’ cells. Space constraints in this minireview prevent us
rom providing a thorough comparison of these two popular
outes of administration.
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233Rational manipulation of DNA vaccines would be best
ndertaken when the mechanism of action of these vac-
ines is fully understood. Perhaps surprisingly, this is far
rom the case. Indeed, the mechanism underlying cyto-
oxic T lymphocyte (CTL) induction even during an ordi-
ary viral infection remains controversial. Some argue
hat CTLs are induced only by proteins synthesized en-
ogenously, within an appropriate APC. In stark contrast,
thers have presented a cogent argument that CTLs are
nduced mainly through “cross-priming,” a process in
hich proteins released from somatic cells are taken up
y specialized APCs (perhaps dendritic cells) and
hereby enter the MHC class I presentation pathway to
nduce CTL. As it applies to DNA vaccination, this ques-
ion is far from academic. For example, if the latter
rgument is true, then an effective DNA vaccine might be
ne which produces a large quantity of protein which will
e secreted from transfected cells (such as muscle cells)
o be taken up by specialized APCs. In contrast, if the
ormer argument is correct, a better DNA vaccine would
nter dendritic cells and synthesize the encoded pro-
eins therein. Dendritic cells have been shown to take up
nd express DNA following both im and id administration
nd, in describing the various ways in which DNA im-
unization may be improved, in this minireview we have
hosen to focus on manipulating antigen presentation in
PCs. Note that antigen presentation has recently been
eviewed in some detail (see Whitton, 1998). In Fig. 1A
e have provided a diagram of an antigen-presenting
ell, showing both the MHC class I and MHC class II
ntigen presentation pathways. Eleven stages have
een identified, each of which may be open to manipu-
ation, to enhance DNA immunization. These stages will
e addressed below in numerical order.
STAGE 1. TARGETING DNA TO ANTIGEN-
PRESENTING CELLS AND ENHANCING
DNA UPTAKEAttempts have been made to target DNA to antigen-
resenting cells. This process may allow us to greatly
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234 MINIREVIEWreduce the quantity of DNA administered, since focusing
it only on cells important to the induction of the immunity
will thereby enhance the immunogenicity of DNA. Again,
FIG. 1. How can we exploit an antigen-presenting cell to enhance D
oxes (1–11) indicating various stages in the process of DNA immuniz
nhance the immunogenicity of inoculated DNA. Both MHC antigen pre
ed dotted line and the class II pathway above it. The three classes of ly
and B cells—are shown interacting with the DNA-encoded sequence
bound or secreted protein (for B cells). (B) Mice were immunized once w
harvested and tested directly ex vivo by intracellular cytokine staining (
alone or the same Th epitope linked to the cytoplasmic tail of LIMP-II. F
was evaluated by ICCS.however, we see that understanding the underlying
mechanisms is important to optimizing the process; if wedo not know which cells are important, we are unable to
appropriately direct the DNA. Once the DNA has reached
the relevant cells, it will be important to increase the
munization? (A) An antigen-presenting cell is shown, with numbered
any of these stages have been exploited, as described in the text, to
on pathways are shown; the class I pathway is summarized below the
yte which mount antigen-specific responses—CD41 and CD81 T cells
appropriate forms: processed peptides (for T cells) and membrane-
er pCMV-MG34 or pCMV-U-MG34. Four weeks later splenocytes were
(C) Mice were immunized with plasmids encoding either a Th epitope
eks later mice were infected with LCMV, and 6 days later the responseNA im
ation; m
sentati
mphoc
s in the
ith eith
ICCS).efficiency of its uptake into the cell and its introduction to
the nucleus where it undergoes transcription. The pro-
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235MINIREVIEWcess of DNA uptake remains ill-understood, although
several lipid transfectants have improved the efficiency
of DNA uptake both in vitro and in vivo.
STAGE 2. ENHANCEMENT OF TRANSCRIPTION
AND TRANSLATION
One attractive way to increase expression of encoded
roteins is to ensure that transcription is maximal in the
ransfected cells. To this end, several promoter systems
ave been evaluated. Most of these employ viral promot-
rs, which often drive high-level transcription, in a large
ariety of cell and tissue types. To date, it appears that
he best promoter remains the immediate-early promoter
rom human cytomegalovirus. As an alternative to using
iral promoters, several groups have attempted to en-
ance transcription in specific cell types by using cell- or
issue-specific promoters. For example, groups have
sed promoters specific for muscle cells and for cells of
he immune system; so far as we are aware, none of
hese have provided marked enhancement over the
ore commonly used promoters. We are not aware of
ny studies undertaken specifically to enhance transla-
ion. However, we have recently found that, particularly
hen using “minigene” DNA vaccines, it is vital that the
ranslational initiation codon is flanked by appropriate
Kozak” sequences (An et al., 2000).
Stages 1 and 2 are common to both MHC pathways,
ut after the gene is transcribed, the fates of the encoded
roteins may differ, depending on the nature of the pro-
eins and any modulatory sequences. Therefore, as
hown in Fig. 1A, stages 3–5 apply only to the MHC class
antigen presentation pathway, while stages 6–10 apply
nly to the MHC class II presentation pathway.
STAGE 3. USING UBIQUITIN TO ENHANCE
ANTIGEN DELIVERY TO THE PROTEASOME
Proteins targeted for synthesis in the cytosol are trans-
ated from mRNAs bound to free ribosomes. A certain
roportion of the resulting endogenously synthesized
rotein is “tagged” with the cellular protein ubiquitin (“Ub”
n Fig. 1A); the attached ubiquitin then serves as a target
or further ubiquitination, resulting in the protein carrying
polyubiquitin chain, which targets the protein to the
roteasome, a cytosolic organelle which appears re-
ponsible for much of the proteolytic degradation within
ells. The protein is degraded by the proteasome into
hort peptides, which pass through the “TAP” transport-
rs into the endoplasmic reticulum (ER). There, a peptide
s selected by a class I MHC molecule on the basis of
inding affinity, and this peptide/MHC complex passes
rom the endoplasmic reticulum through the Golgi com-
lex and eventually reaches the cell surface where it
nteracts with, and induces, CD81 CTL. Several labora-
tories reasoned that enhancing the delivery of the endo-
genously synthesized protein to the proteasome might
p
cresult in increased peptide delivery to the ER and con-
sequently in higher density of peptide/MHC class I com-
plexes on the cell surface, which would in turn lead to
enhanced activation of CTL. Improved delivery to the
proteasome using ubiquitin has been achieved in two
general ways. First, some labs have taken advantage of
the fact that the N-terminal amino acid of a protein
appears to dictate the efficiency with which the protein is
degraded within the cell. By fusing the ubiquitin open
reading frame (ORF) to the ORF encoding the microbial
protein, one can direct the cell to specifically cleave the
ubiquitin from that protein following translation; in this
way one can generate, within the cytosol of a DNA-
transfected cell, a microbial protein with a specified
N-terminal amino acid (different from that present in the
natural protein). By using ubiquitin in this way, to manip-
ulate the N-terminal amino acid of the encoded protein,
it has proved possible to enhance induction of CTL in
vivo (Tobery and Siliciano, 1997; Townsend et al., 1988).
The second approach again fuses ubiquitin to the en-
coded protein, but this time uses a modified ubiquitin
which cannot be cleaved from the protein. This ubiquitin–
protein fusion is efficiently polyubiquitinated and tar-
geted to the proteasome. As a result, proteins attached
to the modified ubiquitin have a very markedly reduced
half-life, due to proteasome-dependent degradation. In
this case, too, CTL induction appears to be enhanced, as
is protective immunity in animal model systems (Rodri-
guez et al., 1997, 1998). Using intracellular cytokine stain-
ing (ICCS), CD81 T cell responses cannot be detected
irectly ex vivo in mice immunized with pCMV-MG34,
hich contains LCMV CTL epitopes encoded as mini-
enes; however, a plasmid containing the same mini-
enes attached to ubiquitin (pCMV-U-MG34) induces a
trong CD81 response, detectable directly ex vivo (Fig.
1B). Taken together, these data appear more consistent
with the idea that CTL are induced by proteins synthe-
sized within transfected APCs than with cross-priming,
because the ubiquitinated proteins are so rapidly de-
graded within the transfected cell that it is difficult to
conceive of their release, uptake, and appropriate pro-
cessing by “bystander” APCs.
STAGE 4. ASSEMBLY OF PEPTIDE MHC
COMPLEXES IN THE ER AND THEIR
TRANSPORT TO THE CELL SURFACE
Much light has recently been shed on the nature of
eptide binding to the MHC, the process of assembling
he trimolecular peptide/MHC/b2m complex, and its
ransport to the cell membrane (see recent chapter by
ourie and Yang, 1998). Such data may in the future allow
s to modify the appropriate epitopes, to enhance MHC
inding while retaining T cell receptor specificity, thus
otentially enhancing the concentration of peptide/MHC
omplexes on the cell surface. Studies on transport of
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236 MINIREVIEWpeptide/MHC complexes have shown significant vari-
ability among the different MHC alleles; until a fuller
understanding of this process is available, it will be
difficult to manipulate it using DNA immunization. Thus,
stage 4 remains relatively refractory to enhancement at
this time.
STAGE 5. INTERACTION BETWEEN NAI¨VE T
CELLS AND STIMULATORY MOLECULES ON THE
SURFACE OF ANTIGEN-PRESENTING CELLS
Naı¨ve CD81 T cells are activated when their T cell
eceptors encounter the appropriate peptide/MHC com-
lex on the surface of APCs. However, this activation
equires contact between costimulatory molecules on
he surfaces of the CD81 T cell and the APC; for example,
etween CD28 on the T cell and B7 on the APC. T cell
ctivation can also be modulated by the cytokine milieu
n the microenvironment; for example, interferon-g can
ncrease the levels of MHC class I complexes, as well as
f certain costimulatory molecules, on the cell surface.
herefore, the likelihood that naı¨ve T cells will be appro-
riately activated can be increased by coadministration
f plasmid DNA encoding costimulatory molecules or
ytokines. Many published studies suggest that both
pproaches can improve the outcome of DNA immuni-
ation.
Above we discuss ways in which MHC class I presen-
ation may be manipulated using DNA immunization. In
he following paragraphs we shall address similar ma-
ipulations involving the MHC class II antigen-present-
ng pathway.
STAGE 6. TARGETING PROTEINS FOR CELL
MEMBRANE DISPLAY OR FOR SECRETION
Proteins entering the class II pathway generally do so
ia recycling from the cell membrane of the APCs in
hich they were made or (more commonly) are shed into
he extracellular milieu before being taken up by APCs.
ollowing recycling from the cell membrane, or uptake
rom the extracellular milieu, proteins destined for the
HC class II pathway enter lysosomes, wherein they
ndergo hydrolysis, generating peptides of approxi-
ately 20–25 amino acids in length. These lysosomes
use with vesicles containing the MHC class II molecules
nd, following binding of an appropriate peptide to the
HC heterodimer, the mature complex is presented on
he cell surface to interact with CD41 T cells. To exploit
these two natural routes of entry into the class II path-
way, plasmid-encoded proteins have been engineered to
ensure secretion or cell membrane localization. This can
be achieved by attaching “signal sequences” to the pro-
tein, resulting in its translation on the membrane-bound
ribosomes of the rough endoplasmic reticulum, entry into
the ER, and subsequent export. One such protein is
shown in Fig. 1A, with the signal sequence represented
a
1by a black bead. Studies in the past few years have
exploited LAMPs (lysosome-associated membrane pro-
teins), which first find their way to the cell membrane
before being recycled into the lysosome pathway. Al-
though not using DNA immunization, the data show that
attachment of foreign proteins to LAMPs can target pro-
teins for lysosomal entry and destruction and enhanced
class II presentation (Rowell et al., 1995; Thomson et al.,
1998; Wu et al., 1995). The effects of addition of other
signal/secretory sequences to plasmid-encoded anti-
gens have been studied for several years, but no clear
pattern has emerged. Some studies suggest that target-
ing proteins for secretion has little effect on the resulting
immune response, while others argue that a statistically
significant effect can be shown.
STAGE 7. DIRECT TARGETING TO LYSOSOMES
The LAMP results illuminate the advantage of target-
ing proteins to the lysosomal pathway but, as stated
above, LAMP targeting is indirect. We have recently
shown the benefit of a more direct route, in which the
cytosolic tail of the LIMP-II protein (lysosomal integral
membrane protein II; shown as an open bead in Fig. 1A)
is attached to the C-terminus of the plasmid-encoded
microbial protein (Rodriguez et al., in preparation). The
resulting fusion protein transits directly from the ER to
the lysosome, with no intervening detour to the cell
surface. Mice were immunized with a plasmid encoding
either a Th epitope alone or a Th epitope attached to
LIMP-II and, 4 weeks later, were restimulated in vivo by
LCMV infection. Six days thereafter, their epitope-spe-
cific CD41 T cell responses were measured by ICCS. As
hown in Fig. 1C, the attachment of the LIMP-II tail
reatly enhanced the induction of IFN-g-producing CD41
T cells (Th1 cells).
STAGE 8. TARGETING DNA-ENCODED
PROTEINS TO APCs
As stated above, many proteins entering the MHC
lass II pathway do so following endocytosis by special-
zed APCs. In addition, it has been argued that many
D81 T cells may be induced by uptake of exogenous
rotein (cross-priming; see above). Therefore, instead of
rying to target the plasmid DNA (or its expression) to
pecific cells, some groups have attempted to enhance
NA immunization by targeting the synthesized protein
o APCs. This method assumes that the proteins synthe-
ized following DNA immunization will be released from
heir cell of origin (e.g., muscle cells, following im inoc-
lation), thus permitting the protein to gain access to
PCs. One elegant study attached foreign sequences to
he CTLA-4 molecule, which targeted it to APCs; the
uthors described enhanced immunity (Boyle et al.,
998).
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237MINIREVIEWSTAGE 9. LYSOSOMAL DEGRADATION
OF PROTEIN
Hydrolysis of the proteins contained in lysosomes ap-
pears to depend in large part on proteases named ca-
thepsins. These enzymes have been the subject of much
recent study, and identification of the requirements for
cathepsin cleavage may permit the design of proteins
which are more efficiently cleaved or are cleaved with
modified specificity. However, so far as we are aware,
this approach has not been applied to DNA immuniza-
tion.
STAGE 10. ENHANCEMENT OF CD41
T CELL ACTIVATION
In a manner analogous to that discussed above at
stage 5, the activation of naı¨ve CD41 T cells may be
anipulated by the coadministration of plasmids encod-
ng costimulatory molecules such as CD40 ligand (Men-
oza et al., 1997) and/or cytokines.
STAGE 11. INDUCING ANTIBODIES
The foregoing has focused solely on induction of T cell
mmunity. Obviously, successful antiviral vaccines must
nduce virus-specific antibody responses. Biologically
elevant antibodies interact with intact microbial pro-
eins, rather than with fragments thereof; biologically
elevant antibodies will most often be induced by intact
roteins, and these are present either on the surface of
he organism or on the membrane of the infected cell. As
artooned in Fig. 1A, intact proteins can be targeted to
he cell membrane, or for secretion, to make them avail-
ble to interact with antibodies expressed on the mem-
rane of B cells. In this light, it is relevant to note that the
se of ubiquitin to enhance intracellular degradation has,
s an unintended consequence, also greatly reduced the
nduction of antibodies specific for the plasmid-encoded
ntigen. Thus, as we enhance the degradation of a pro-
ein, we decrease the quantity of intact material available
o B cells and thereby reduce the efficiency of antibody
nduction. Is the converse also true—does the enhance-
ent of cell membrane expression, or secretion, of a
lasmid-encoded protein enhance the antibody re-
ponse induced by DNA immunization? As stated above,
everal laboratories have attempted to enhance DNA
mmunization using these approaches, and while some
ave reported modest success, no such approach has
et led to a massive improvement in the quantity and/or
uality of antibody induced by DNA immunization. How-
ver, the linkage of an antigen to CTLA-4, described
bove, produced a logarithmic increase in antibody titers
nd appears extremely promising.
In summary, one enormous advantage of DNA immu-
ization is its flexibility, which allows us to blend specific
ocktails for specific appetites. For example, one can
Tmagine a DNA vaccine containing at least four kinds of
lasmid: first, a plasmid expressing a ubiquitinated an-
igen, to direct it toward the MHC class I pathway, thus
nhancing CTL induction; second, a plasmid expressing
he identical antigen, but targeted to the MHC class II
athway, thus inducing CD41 T cells; third, a plasmid
targeting the antigen to B cells; and fourth, plasmids
encoding costimulatory molecules and/or cytokines. This
description applies to a single antigen, but the cocktail
becomes even more intoxicating when one applies a
further advantage of DNA vaccines; they overcome the
space restrictions which limit most other vector-medi-
ated approaches. Therefore, a single vaccine may in-
clude all of the above plasmids, but repeated manifold,
for many different antigens. Enhancing DNA vaccination
promises to be a fertile field, from which the harvest has
only just begun.
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